glp 1 agonists ozempic New GLP-1; Semaglutide (Ozempic) POTD: Wegovy and Ozempic —
Description
How do they work
This analytical review critically examines the evidence surrounding GLP-1 agonists efficacy, safety, and real-world implications for obesity treatment in individuals without diabetes
GLP-1R agonist 2 has the potential for research in metabolic diseases such as type 2 diabetes and obesity
95% CI 0.97, 1.15)
In a phase 2 study, amycretin showed a mean weight reduction of up to 24.3%, which is comparable to or even greater than the weight loss seen with tirzepatide and similar to the results for retatrutide
A new era for weight loss
